Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs
Citations Over TimeTop 10% of 2011 papers
Abstract
The widely employed anti-diabetic drug pioglitazone (Actos) is shown to be a specific and reversible inhibitor of human monoamine oxidase B (MAO B). The crystal structure of the enzyme-inhibitor complex shows the R-enantiomer is bound with the thiazolidinedione ring near the flavin. The molecule occupies both substrate and entrance cavities of the active site establishing non-covalent interactions with the surrounding amino acids. These binding properties differentiate pioglitazone from the clinically used MAO inhibitors, which act through covalent inhibition mechanisms and do not exhibit a high degree of MAO A versus B selectivity. Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson's patients. They also provide new insights for the development of reversible isoenzyme-specific MAO inhibitors.
Related Papers
- → Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease(2011)120 cited
- → Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?(2008)28 cited
- → Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes(2009)
- The comparison study of pioglitazone and rosiglitazone on type 2 diabetes with hyperlipemia(2009)
- → Cardiovascular safety of rosiglitazone and pioglitazone(2015)